NCT00291369View on ClinicalTrials.gov

Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis

PHASE3CompletedINTERVENTIONAL
Enrollment

456

Participants

Timeline

Start Date

December 31, 1999

Study Completion Date

February 28, 2005

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Interleukin-2

DRUG

Interferon alfa

DRUG

medroxyprogesterone acetate

Trial Locations (1)

69008

Centre Leon Berard, Lyon

All Listed Sponsors
collaborator

French Immunotherapy Intergroup

OTHER

collaborator

SCAPP (Sub-Cutaneous Administration Proleukin Program)

UNKNOWN

lead

Centre Leon Berard

OTHER

NCT00291369 - Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis | Biotech Hunter | Biotech Hunter